From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer

Last Updated: Wednesday, January 27, 2021

This study prospectively assessed comprehensive next-generation sequencing of cell-free circulating tumor DNA (cfDNA) compared with standard-of-care tissue-based testing and found that cfDNA assay is noninferior to tissue testing in identifying targetable alterations.

JCO Precision Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement